Bromazolam: Complete Evidence, Toxicology, Dependence, Withdrawal & Safety Monograph

Bromazolam: Complete Evidence, Toxicology, Dependence, Withdrawal & Safety Monograph

Emergency safety: A person who cannot be awakened, has slow or irregular breathing, is blue/gray around the lips, is choking or gurgling while unresponsive, has a seizure, or collapses after an unknown pill or powder needs emergency care. Bromazolam frequently appears with fentanyl and other depressants. Naloxone reverses opioids, not benzodiazepines, but it should still be given when opioid exposure is possible because the product may contain or be co-used with an opioid. Persistent sedation or abnormal breathing still requires emergency care.

Quick answer

Bromazolam is an unapproved triazolobenzodiazepine closely related to alprazolam. It was originally developed as a candidate medication but was never approved for therapeutic use. Government monitoring first documented it in Sweden in 2016; it later spread through European and North American drug markets, especially in counterfeit tablets and mixtures involving fentanyl. WHO critical review

The best modern evidence does not come from clinical trials. It comes from toxicology laboratories, emergency departments, impaired-driving investigations, seized-drug analysis, and postmortem surveillance. That evidence now shows bromazolam is a major public-health and forensic drug rather than a niche “research chemical.”

The biggest misconception is that bromazolam can be treated as a predictable substitute for alprazolam. There is no validated milligram-for-milligram equivalence, no controlled therapeutic dose, no established safe recreational dose, and no reliable toxic blood concentration. Counterfeit tablets may also vary in strength or contain other drugs.

A second critical misconception is that dependence means addiction. Regular benzodiazepine exposure can produce physical dependence even without compulsive behavior. A benzodiazepine use disorder involves a broader pattern of impaired control and continued use despite harm. Both matter, but they are not the same diagnosis. Joint Clinical Practice Guideline, PMID 40526204

---

Evidence at a glance

---

Identity: what exactly is bromazolam?

Canonical name: Bromazolam
CAS: 71368-80-4
Class: triazolobenzodiazepine / designer benzodiazepine
Structural relationship: brominated analogue of alprazolam
Therapeutic approval: none established
Common market context: counterfeit “Xanax”- or diazepam-like tablets, powders, mixed illicit drug supply

The WHO describes bromazolam as 8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine. It belongs to the same broad triazolobenzodiazepine family as alprazolam but is a distinct molecule with its own metabolism, forensic profile and regulatory status. WHO critical review

Bromazolam is not alprazolam with a known conversion factor

The structural similarity is useful for understanding mechanism. It is not enough to establish clinical equivalence.

A genuine prescription alprazolam tablet has a regulated identity and labeled amount. A street tablet represented as alprazolam may contain bromazolam, another designer benzodiazepine, fentanyl, multiple drugs, or an unexpectedly high/low amount of the intended drug.

That is why this site intentionally does not publish bromazolam-to-alprazolam “equivalence” charts.

---

History: from abandoned medicinal chemistry to counterfeit-drug market

Bromazolam was originally investigated as a potential medication but never received marketing approval. WHO reports the first government detection in Sweden in 2016. By the 2023 WHO critical review, the compound had been identified in products or biological samples across numerous countries. WHO

U.S. forensic literature places its emergence around 2019–2020, followed by substantial growth during 2021–2025. Indiana, Texas, California, Virginia and other jurisdictions later documented sharp increases. PMID 38896045 PMID 39275788 PMID 38679868 PMID 42057452

The history is important because it shows market substitution: designer benzodiazepines can rise and fall as scheduling, supply and counterfeit-pill production change.

---

Pharmacology: why bromazolam causes sedation, amnesia and impairment

GABA-A positive allosteric modulation

Bromazolam acts at the benzodiazepine site of GABA-A receptors. Benzodiazepine-site positive allosteric modulators do not simply “turn on” the receptor by themselves; they enhance the effect of the inhibitory neurotransmitter GABA at susceptible receptor subtypes.

That mechanism can produce the familiar benzodiazepine spectrum:

• anxiolysis;
• sedation;
• hypnosis;
• muscle relaxation;
• anticonvulsant effects;
• slowed psychomotor performance;
• impaired memory formation;
• impaired coordination.

WHO's review cites receptor studies showing bromazolam binding at benzodiazepine-sensitive GABA-A receptor subtypes and functional enhancement of GABA-A signaling. These are valuable mechanistic data, but receptor affinity should not be translated into a human dose-equivalence calculation. WHO

Why memory impairment matters

Benzodiazepines can impair the formation of new memories while a person remains awake and behaviorally active. That creates a distinctive harm pattern: the person can continue taking substances, driving, communicating or moving around without forming reliable memories of what happened.

This is one reason retrospective dose histories after designer-benzodiazepine exposure can be unreliable.

---

Metabolism and pharmacokinetics

Direct controlled human pharmacokinetics are limited.

A 2021 toxicokinetic study identified bromazolam metabolites in human plasma and urine and found that metabolism involved several CYP enzymes, with CYP3A4 participating in the formation of all identified phase-I metabolites in the experimental system. Phase-II glucuronidation pathways were also characterized. PMID 33048135

Important urinary screening targets identified in that work included hydroxy-bromazolam conjugates and bromazolam glucuronides.

What remains unknown

The literature does not provide the kind of validated population PK model available for an approved medicine. Important uncertainties include:

• reliable oral bioavailability;
• a well-defined human elimination half-life across populations;
• effect of liver disease;
• effect of kidney disease;
• magnitude of CYP-mediated drug interactions;
• exposure-response relationships;
• dose-to-blood-concentration relationships in unregulated products.

For those reasons, online claims about exact onset, half-life or “how long it lasts” should not be treated as clinical facts unless tied to analytical evidence.

---

Counterfeit pills and unintentional exposure

This is one of the most important bromazolam safety issues.

A 2026 UK analysis of submitted tablets found that 55% mimicked licensed alprazolam or diazepam products. The same study documented substantial variability and linked those product findings to national mortality surveillance. PMID 41732118

The practical consequence is straightforward:

A tablet stamped or shaped like a prescription benzodiazepine does not prove that it contains that medication.

The problem is not limited to people intentionally seeking designer benzodiazepines.

In a 2025 prospective U.S. emergency-department toxico-surveillance study, 28 of 341 patients were bromazolam-positive. Among bromazolam-positive patients who reported intending to use only one substance, none reported intending to use bromazolam; intended fentanyl and heroin use were common. PMID 40652609

That finding is unusually important for harm reduction because it documents unintentional exposure, not merely voluntary RC use.

---

Human intoxication: what clinicians and forensic investigators actually see

Bromazolam's expected clinical picture resembles other benzodiazepine-type CNS depressants:

• marked sleepiness;
• slowed reaction time;
• slurred speech;
• incoordination;
• impaired attention;
• memory impairment;
• reduced consciousness.

Severe presentation becomes more dangerous when opioids, alcohol or other sedatives are present.

Impaired-driving evidence

A 2024 study reported 98 bromazolam-positive impaired-driving investigations from 2021–2023. Observed behavior included erratic driving, field-sobriety-test errors, slurred speech, poor coordination and lethargy. Additional drugs were present in nearly all cases, with fentanyl the most common co-detected drug. PMID 39191669

This is useful human evidence because it demonstrates real-world functional impairment rather than merely receptor activity.

---

Fatality and postmortem evidence

Bromazolam now has a large forensic mortality literature.

United Kingdom

A 2026 national study reported bromazolam in 396 drug-related deaths between April 2021 and July 2024. Detections rose sharply over time. Bromazolam was considered contributory in many cases, but an average of roughly seven additional substances were detected per case. PMID 41732118

Travis County, Texas

A study covering 2021–2023 identified bromazolam in 112 deaths. Polydrug exposure occurred in 99% of bromazolam-positive deaths; fentanyl was present in 82% of drug-toxicity cases involving bromazolam. PMID 39275788

Indiana

Indiana forensic laboratories identified bromazolam in 94 postmortem cases during 2023, and fentanyl was present in 83 of them. Bromazolam was included in the certified cause of death in 31 cases. PMID 38896045

San Francisco

San Francisco documented a sharp increase in bromazolam-associated fatalities during 2023, often involving fentanyl and stimulants. PMID 38679868

Why there is no simple “lethal level”

Postmortem bromazolam concentrations overlap across cases and are influenced by:

• tolerance;
• timing;
• other depressants;
• fentanyl exposure;
• individual physiology;
• postmortem redistribution;
• analytical method;
• uncertainty about the amount consumed.

A 2026 paper specifically examined postmortem redistribution for bromazolam and other designer benzodiazepines, reinforcing why a single concentration should not be used as a universal fatal threshold. PMID 42216246

---

Bromazolam + fentanyl: the central modern overdose problem

Across multiple U.S. datasets, bromazolam is repeatedly found alongside fentanyl.

Examples include:

• Indiana: fentanyl in 83 of 94 bromazolam-positive postmortem cases; PMID 38896045
• Travis County: fentanyl in 82% of bromazolam-related drug toxicities; PMID 39275788
• Virginia: in Q2 2025, fentanyl was present in a large majority of bromazolam-positive toxicology specimens and in many seized-drug cases. PMID 42057452
• U.S. ED surveillance: bromazolam-positive overdose patients commonly reported intending to use opioids rather than bromazolam. PMID 40652609

Why the combination is dangerous

Opioids directly suppress respiratory drive. Benzodiazepine-type drugs add sedation, reduce arousal and can impair airway-protective responses.

The danger is therefore not adequately described as “two sedatives added together.” The combined exposure can make a person less able to respond as opioid-induced respiratory depression worsens.

CDC identifies benzodiazepine + opioid exposure as a major overdose risk. CDC overdose risk guidance

Naloxone: useful, but not a bromazolam antidote

Naloxone reverses opioid receptor effects. It does not reverse benzodiazepine intoxication.

If an unknown pill or powder may contain fentanyl or another opioid, giving naloxone is appropriate because it can reverse the opioid portion of the overdose. Persistent sedation can remain after naloxone if a benzodiazepine is also present.

Call emergency services even when naloxone appears to work.

---

Other interaction risks

Alcohol

Alcohol and benzodiazepine-type drugs both impair coordination, judgment and consciousness. The combination increases the risk of severe sedation, aspiration, accidents and respiratory compromise.

Other benzodiazepines or sedative-hypnotics

Stacking multiple GABAergic sedatives can produce disproportionate impairment and amnesia.

Gabapentinoids, muscle relaxants and other CNS depressants

These combinations can increase sedation and impairment. The magnitude of bromazolam-specific interaction has not been quantified.

CYP interactions

Because CYP3A4 is involved in bromazolam phase-I metabolism in experimental studies, medications or substances that strongly alter CYP3A activity could plausibly alter exposure. The exact clinical magnitude has not been validated for bromazolam.

---

Tolerance

Tolerance means the same exposure produces less of an effect over time.

Direct prospective bromazolam tolerance studies do not exist, but tolerance is a well-established property of benzodiazepine pharmacology.

Tolerance is dangerous for two reasons:

1. it can drive escalating or more frequent use;
2. after a period of reduced use or abstinence, prior exposure patterns may become much more impairing.

Tolerance to subjective sedation also does not guarantee protection from memory impairment, accidents or polysubstance overdose.

---

Physical dependence: what it means

Physical dependence is a neuroadaptation in which abrupt reduction or discontinuation produces withdrawal.

It can occur without addiction.

The 2025 Joint Clinical Practice Guideline on Benzodiazepine Tapering emphasizes that physical dependence is expected in many people who take benzodiazepines regularly and is distinct from benzodiazepine use disorder. PMID 40526204

For bromazolam, direct longitudinal studies are absent. However, given its benzodiazepine-site pharmacology, repeated regular exposure should be treated as capable of producing clinically meaningful physical dependence.

---

Benzodiazepine use disorder: dependence is not the whole story

A substance use disorder involves a broader pattern of impaired control and continued use despite harm.

Warning signs can include:

• repeated unsuccessful attempts to cut down;
• craving or strong urges to use;
• escalating time spent obtaining, using or recovering;
• continued use despite injuries, relationship problems or work problems;
• using in hazardous situations;
• continuing despite knowing the drug is worsening physical or mental health;
• tolerance;
• withdrawal.

A person can be physically dependent without having all of these features.

Conversely, counterfeit-pill use can create a substance-use problem even when the person does not know which benzodiazepine they are receiving.

---

Withdrawal: one of the most important sections on this page

What is known specifically about bromazolam?

There is no validated bromazolam-specific withdrawal timeline or taper protocol.

The lack of a dedicated trial does not mean withdrawal is safe. It means clinicians must rely on benzodiazepine class evidence plus the person's actual exposure pattern, symptoms, co-use and medical history.

Benzodiazepine withdrawal can include

• rebound anxiety;
• severe insomnia;
• tremor;
• sweating;
• nausea;
• agitation;
• perceptual disturbances;
• sensitivity to sound/light;
• muscle symptoms;
• confusion.

Severe withdrawal can include:

• seizures;
• delirium;
• hallucinations;
• severe autonomic instability;
• dangerous agitation.

The ASAM-led 2025 guideline warns against abrupt discontinuation in physically dependent patients and emphasizes gradual, individualized, clinically supervised reduction rather than one-size-fits-all schedules. ASAM PMID 40526204

Why designer-benzodiazepine withdrawal is especially hard to predict

With bromazolam, the person may not know:

• the actual amount in each tablet;
• whether every tablet contains the same amount;
• whether another benzodiazepine is present;
• whether fentanyl or another depressant is present;
• the true average daily exposure;
• the true elimination time in their body.

That makes internet equivalence charts particularly unreliable.

When medical assessment becomes especially important

Urgent or medically supervised assessment is particularly important when there is:

• a history of withdrawal seizure;
• current seizure or delirium;
• severe confusion or hallucinations;
• heavy or frequent daily use;
• use of multiple benzodiazepines;
• alcohol dependence;
• opioid co-use;
• pregnancy;
• significant medical illness;
• inability to safely monitor symptoms.

This is not a moral judgment. It is a risk problem.

---

Treatment and support for bromazolam dependence or addiction

There is no FDA-approved medication specifically for “bromazolam addiction,” and there is no validated bromazolam-specific detox protocol.

Evidence-based care usually comes from benzodiazepine withdrawal management + treatment of any co-occurring substance use disorder + treatment of the original anxiety/insomnia/trauma problem when present.

Useful components can include:

• medical assessment of seizure and withdrawal risk;
• a clinician-managed benzodiazepine taper when appropriate;
• treatment of co-occurring opioid, alcohol or stimulant use disorders;
• cognitive behavioral therapy and other evidence-based psychotherapy;
• treatment of anxiety, insomnia, PTSD or depression with non-benzodiazepine strategies when appropriate;
• peer/recovery support;
• overdose-prevention planning when opioid exposure is possible.

The 2025 multidisciplinary guideline recommends patient-centered, individualized tapering rather than abrupt cessation for people who are physically dependent. ASAM guideline

For U.S. readers seeking treatment, FindTreatment.gov is SAMHSA's confidential treatment locator, and SAMHSA's National Helpline provides 24/7 treatment-referral information at 1-800-662-HELP (4357). SAMHSA

---

Drug testing and analytical detection

Designer benzodiazepines create a recurring testing problem.

Routine immunoassays

Some benzodiazepine immunoassays may cross-react with bromazolam or its metabolites; others may perform poorly.

That means:

• a positive class screen does not prove bromazolam;
• a negative class screen does not reliably exclude bromazolam.

Confirmatory methods

Published forensic work uses methods including:

• LC-QTOF-MS;
• LC-MS/MS;
• GC-MS with appropriate validation;
• high-resolution mass spectrometry.

A 2021 metabolism study recommended specific bromazolam metabolites as useful urine screening targets. PMID 33048135

Why metabolite knowledge matters

When a parent drug is present at low concentrations or has been metabolized substantially, looking for the correct metabolites can improve detection.

This matters in:

• emergency toxicology;
• impaired-driving cases;
• postmortem investigations;
• drug-facilitated crime investigations.

This page does not provide test-evasion information.

---

Forensic interpretation: what a positive bromazolam result can and cannot prove

A positive result proves that bromazolam or an appropriate metabolite was detected using the stated analytical method.

It does not automatically prove:

• that bromazolam caused the death;
• that bromazolam was knowingly taken;
• that the person took a specific amount;
• that a specific pill contained a specific amount;
• when exactly the exposure occurred;
• that other drugs were unimportant.

Modern bromazolam cases are frequently polysubstance cases.

That distinction is essential when interpreting death counts and blood concentrations.

---

Current epidemiology: the trend is real

Several independent datasets show rapid growth rather than an isolated local cluster.

Virginia

From 2021 through Q2 2025, Virginia observed increasing bromazolam detection in both toxicology and seized-drug casework. In Q2 2025, fentanyl was present in a large share of bromazolam-positive antemortem, postmortem and seized-drug cases. PMID 42057452

Texas, Indiana and San Francisco

Separate studies show substantial increases in postmortem bromazolam detection across all three regions. PMID 39275788 PMID 38896045 PMID 38679868

United Kingdom

National mortality surveillance documented hundreds of bromazolam-positive drug-related deaths between 2021 and 2024. PMID 41732118

These populations are not interchangeable, but the direction of the evidence is consistent: bromazolam became a major component of the contemporary illicit sedative supply.

---

Legal and regulatory history

International

WHO critically reviewed bromazolam and recommended international control. The UN Commission on Narcotic Drugs placed bromazolam in Schedule IV of the 1971 Convention on Psychotropic Substances in 2024; the scheduling decision became fully effective later that year. INCB 2024 report

United States

DEA temporarily placed bromazolam in Schedule I of the Controlled Substances Act effective March 16, 2026, with the temporary order scheduled through March 16, 2028 unless extended or replaced by permanent scheduling. Federal Register temporary order

State controls can be stricter or can predate federal action.

Legal status is jurisdiction- and date-specific. This section is informational, not legal advice.

---

Special populations and higher-risk situations

Direct bromazolam-specific research is sparse in these groups, so caution is based mainly on benzodiazepine class evidence.

Risk is especially concerning in:

• people using opioids;
• people with alcohol dependence;
• people with sleep apnea or other respiratory disease;
• people with a history of withdrawal seizures;
• older adults with fall risk;
• people driving or operating machinery;
• pregnancy or breastfeeding;
• people taking multiple sedating medications.

The absence of bromazolam-specific trials in these populations is not evidence of safety.

---

Myths and misconceptions

“It is just brominated Xanax.”

No. It is structurally related to alprazolam, but it is an unapproved compound with different evidence, metabolism, product quality and regulatory status.

“A Xanax-looking pill tells you what is inside.”

No. Counterfeit tablets containing bromazolam are directly documented.

“If fentanyl was not requested, fentanyl is not relevant.”

No. Bromazolam frequently appears in fentanyl-associated toxicology and drug materials, and prospective ED data show unintentional bromazolam exposure among people intending to use opioids.

“Naloxone will reverse the whole overdose.”

No. Naloxone reverses the opioid component. Benzodiazepine sedation can remain.

“A negative benzo screen rules it out.”

No. Routine immunoassay performance varies; targeted mass spectrometry may be required.

“If someone is dependent, they are automatically addicted.”

No. Physical dependence and substance use disorder overlap but are distinct concepts.

“A fatal blood concentration tells me the dangerous dose.”

No. Postmortem concentrations cannot be converted into a personal dose threshold.

---

What we know vs what remains unknown

Established

• bromazolam is a triazolobenzodiazepine with benzodiazepine-site GABA-A activity;
• it is present in counterfeit tablets and illicit drug markets;
• it can impair driving and coordination;
• it appears in nonfatal overdose surveillance and large postmortem datasets;
• fentanyl co-detection is common;
• targeted toxicology can identify it and its metabolites;
• it is federally controlled in the U.S. and internationally scheduled.

Strongly plausible from class evidence

• repeated use can produce physical dependence;
• abrupt discontinuation after dependence can produce dangerous benzodiazepine withdrawal;
• alcohol, opioids and other sedatives increase risk;
• tolerance and cross-tolerance can occur.

Not established

• a safe recreational dose;
• a validated alprazolam-equivalence ratio;
• a reliable human half-life across populations;
• a universal toxic or lethal blood concentration;
• a bromazolam-specific withdrawal timeline;
• a bromazolam-specific taper protocol;
• long-term controlled human safety.

---

If bromazolam use is becoming hard to control

Signs that it is worth seeking help include:

• needing it to feel normal;
• repeated withdrawal symptoms;
• failed attempts to cut down;
• blackouts;
• escalating amounts or frequency;
• using despite overdose, injuries or relationship/work problems;
• combining it with opioids or alcohol;
• fear of stopping because of withdrawal.

For regular benzodiazepine-type use, do not assume suddenly stopping is safe.

A medical or addiction-medicine clinician can assess withdrawal and seizure risk and help build a safer plan. U.S. readers can use FindTreatment.gov or SAMHSA's National Helpline at 1-800-662-HELP (4357).

If someone is unresponsive, seizing, delirious, or breathing abnormally, that is an emergency rather than a routine treatment-referral situation.

---

Bottom line

Bromazolam is now one of the most important designer benzodiazepines in North American and European forensic toxicology.

Its modern risk is not captured by calling it “an alprazolam analogue.”

The real risk picture is the combination of:

• potent benzodiazepine pharmacology;
• unreliable product identity and tablet strength;
• counterfeit pharmaceutical appearance;
• frequent fentanyl co-exposure;
• profound impairment and amnesia;
• physical dependence and potentially dangerous withdrawal;
• incomplete routine toxicology detection;
• limited controlled human pharmacology.

The most defensible harm-reduction stance is therefore uncertainty-aware, not potency-chart-driven: treat unverified tablets as chemically uncertain, take opioid co-exposure seriously, avoid abrupt discontinuation when dependence is likely, and use medical/addiction support when use becomes difficult to control.

Related evidence

• Designer benzodiazepines / RC benzos
• Clonazolam
• Flualprazolam
• Flubromazolam
• Phenazolam / clobromazolam
• Desalkylgidazepam / bromonordiazepam
• Research chemicals & NPS evidence map
• Substance Use, Dependence & Harm Reduction hub